The drug, marketed under the brand name Tzield and based on the active antibody teplizumab, has shown promising results in clinical trials. It is designed to intervene in the disease's progression ...

Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial – equivalent to almost $194,000 for its 14-day course – a higher level than had been ...

Sanofi has agreed a deal to buy US biopharma company Provention Bio for $2.9 billion, taking control of a recently-approved type 1 diabetes (T1D) prevention therapy Tzield that has been tipped as ...

Pero hay un inconveniente. En sus primeras etapas, la diabetes no causa síntomas, pero el medicamento, comercializado como Tzield, solo es efectivo durante esta fase silenciosa. Esta es la ...